Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"HitGen","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and Evotec SE Enter Into Drug Discovery Research Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"HitGen","sponsor":"Morphic Therapeutic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and Morphic Extend Drug Discovery Research Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery"},{"orgOrder":0,"company":"HitGen","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and Almirall Announce Achievement of Milestoneinn their Strategic Collaboration","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"HitGen","sponsor":"Guangzhou Baiyunshan Pharmaceutical Holdings","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.8 million","newsHeadline":"HitGen Licenses Its Trk\/ROS1 Inhibitor HG030 to Baiyunshan for Development and Commercialisation in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"HitGen","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen Announces License Agreement with Merck to Access Compounds for Potential Development of A Novel Class of Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"HitGen","sponsor":"UPPTHERA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and UPPTHERA Enter Into Drug Discovery Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"HitGen","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen Has Successfully Completed a Three-Year Collaboration With MTPC to Discover Novel Hit Compounds for Multiple Drug Targets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"HitGen","sponsor":"Uppthera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and UPPTHERA Extend PROTAC Research Collaboration After Hit Finding Success on Undruggable Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"HitGen","sponsor":"ARase Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by HitGen

    Menu

    HitGen

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              HitGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics

              Details:

              Under the agreement, HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify novel inhibitors of ARase's validated oncology targets.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: ARase Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HitGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HitGen and UPPTHERA Extend PROTAC Research Collaboration After Hit Finding Success on Undruggable Targets

              Details:

              During the collaboration, multiple undisclosed targets were screened against HitGen’s proprietary over 1 trillion DNA-encoded libraries (DELs). The majority of the targets have resulted in confirmed hits, which have high potential for PROTAC development.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Uppthera

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HitGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HitGen Has Successfully Completed a Three-Year Collaboration With MTPC to Discover Novel Hit Compounds for Multiple Drug Targets

              Details:

              During the three-year collaboration, multiple undisclosed targets (including undruggable targets) were screened against HitGen’s proprietary DNA encoded chemical libraries (DELs). The majority of the targets have resulted in confirmed novel potent hits.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Mitsubishi Tanabe Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HitGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HitGen and UPPTHERA Enter Into Drug Discovery Research Collaboration

              Details:

              HitGen has entered into a drug discovery research collaboration with UPPTHERA Inc. to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase. Identified compounds will be exclusively licensed to UPPTHERA for further development.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: UPPTHERA

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HitGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HitGen Announces License Agreement with Merck to Access Compounds for Potential Development of A Novel Class of Drugs

              Details:

              HitGen and Merck have expand their collaboration with a license to develop a novel class of drugs for an early target of high interest. HitGen will grant exclusive rights to Merck & Co., Inc Kenilworth, NJ USA to develop and commercialize the licensed compounds.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Merck & Co

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration December 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HitGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HitGen Licenses Its Trk/ROS1 Inhibitor HG030 to Baiyunshan for Development and Commercialisation in China

              Details:

              Baiyunshan will get exclusive rights to develop and market HG030 in mainland China, and will pay HitGen an upfront licensing fee and a series of milestones and royalty of sales as the product progresses through clinical trials and launches in the mainland China.

              Lead Product(s): HG030

              Therapeutic Area: Oncology Product Name: HG030

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Guangzhou Baiyunshan Pharmaceutical Holdings

              Deal Size: Undisclosed Upfront Cash: $5.8 million

              Deal Type: Licensing Agreement November 10, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HitGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HitGen and Almirall Announce Achievement of Milestoneinn their Strategic Collaboration

              Details:

              Multiple small molecule leads for an undisclosed target nominated by Almirall were the subject of this achievement. HitGen will grant exclusive rights to Almirall for further development and commercialization, and be eligible for preclinical and clinical milestone payments.

              Lead Product(s): Undisclosed

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: Almirall

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration August 26, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HitGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HitGen and Morphic Extend Drug Discovery Research Collaboration

              Details:

              Under the terms of the extended agreement, HitGen will use its platform technology, based on the design, synthesis and interrogation by selection of DELs to discover ligands for targets of interest to Morphic.

              Lead Product(s): Undisclosed

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Morphic Therapeutic

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HitGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HitGen and Evotec SE Enter Into Drug Discovery Research Collaboration

              Details:

              HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to identify small molecule leads against targets of interest to Evotec SE in the field of anti-infectives.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Evotec

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY